Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia-Reference-Cited by-同舟云学术

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

Published:2004 Issue:12 Volume:101 Page:2788-2801
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop,Thomas Deborah,O'Brien Susan,Cortes Jorge,Giles Francis,Jeha Sima,Bueso-Ramos Carlos E.,Pierce Sherry,Shan Jianqin,Koller Charles,Beran Miloslav,Keating Michael,Freireich Emil J.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference48 articles.

1. The biology and therapy of adult acute lymphoblastic leukemia

2. TREATMENT OF ADULT ALL ACCORDING TO PROTOCOLS OF THE GERMAN MULTICENTER STUDY GROUP FOR ADULT ALL (GMALL)

3. THE MEDICAL RESEARCH COUNCIL TRIALS IN ADULT ACUTE LYMPHOCYTIC LEUKEMIA

4. ADULT ACUTE LYMPHOCYTIC LEUKEMIA STUDY TESTING CHEMOTHERAPY AND AUTOLOGOUS AND ALLOGENEIC TRANSPLANTATION

5. RECENT CLINICAL TRIALS IN ACUTE LYMPHOCYTIC LEUKEMIA BY THE CANCER AND LEUKEMIA GROUP B

Cited by 521 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial;Journal of Hematology & Oncology;2024-09-02

2. Expanding Beyond Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia: A Pathway-Based Stratification of Patients for Precision Oncology;OMICS: A Journal of Integrative Biology;2024-09-01

3. Research progress on the role and mechanism of Sirtuin family in doxorubicin cardiotoxicity;Phytomedicine;2024-07

4. Acute lymphoblastic leukaemia;Nature Reviews Disease Primers;2024-06-13

5. Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities;Annals of Hematology;2024-06-05